News

NEI News

Cross-sectional images of retina from retinoschisin-deficient mice, untreated and treated with XLRS gene therapy.

The National Eye Institute (NEI) recently launched the first-ever human gene therapy trial for the vision disorder X-linked retinoschisis (XLRS). Researchers are conducting the trial at the National Institutes of Health Clinical Research Center in Bethesda, Maryland.

Posted on Apr 6, 2015
 If a study participant were instructed to pay attention to “scenes” and he was attending well, he would be shown the top image as a reward. As his attention lapsed, the middle and bottom images would be shown. The face in the photograph is that of the study’s first author, Megan deBettencourt, a doctoral candidate at the Princeton Neuroscience Institute.

People are bad at staying focused. We’ve all had our minds wander when we try to concentrate on a task that requires paying close attention but isn’t all that engaging. But a new NIH-funded study suggests that one’s capacity to stay focused can improve with real-time feedback.

Posted on Feb 18, 2015
Illustration showing the retina as seen through a dilated pupil.

In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse at the start of the trial.

Posted on Feb 18, 2015

Budget and Congress

The NEI budget is approximately $675 million (FY2014). The NEI budget requests are submitted to Congress with other NIH institutes as part of the President’s budget request in February. See our Congressional Justifications.